2024
Association Between Hematoma Volume and Risk of Subsequent Ischemic Stroke: A MISTIE III and ATACH-2 Analysis
Harris W, Kaiser J, Liao V, Avadhani R, Iadecola C, Falcone G, Sheth K, Qureshi A, Goldstein J, Awad I, Hanley D, Kamel H, Ziai W, Murthy S. Association Between Hematoma Volume and Risk of Subsequent Ischemic Stroke: A MISTIE III and ATACH-2 Analysis. Stroke 2024, 55: 541-547. PMID: 38299346, PMCID: PMC10932908, DOI: 10.1161/strokeaha.123.045859.Peer-Reviewed Original ResearchMeSH KeywordsAntihypertensive AgentsCerebral HemorrhageFemaleHematomaHumansIschemic StrokeMaleMiddle AgedStrokeTissue Plasminogen ActivatorTreatment OutcomeConceptsIntracerebral hemorrhage volumeMedian ICH volumeRisk of ischemic strokeHematoma volumeIntracerebral hemorrhageIncreased risk of ischemic strokeATACH-2ICH volumeIschemic strokeCumulative incidenceMISTIE IIIIncreased riskLong-term increased riskIntracerebral hemorrhage characteristicsMedian hematoma volumeHeterogeneous cohort of patientsMedian follow-upPrimary analysisIntracerebral hemorrhage locationCohort of patientsNontraumatic intracerebral hemorrhageCox regression analysisShort-term risk of ischemic strokeCox regression modelsIndividual patient data
2023
Effect of Alteplase on Ischemic Stroke Mortality Is Dependent on Stroke Severity
de Havenon A, Abbasi M, Yaghi S, Delic A, Bangad A, Johnston K, Tirschwell D, Sheth K. Effect of Alteplase on Ischemic Stroke Mortality Is Dependent on Stroke Severity. Annals Of Neurology 2023, 93: 1106-1116. PMID: 36852919, DOI: 10.1002/ana.26621.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAtrial FibrillationFemaleFibrinolytic AgentsHumansIschemic StrokeStrokeThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsIV-tPAHigher NIHSSIschemic strokeAtrial fibrillationNational Inpatient Sample (NIS) 2016Non-Hispanic white raceOlder ageBaseline National InstitutesDEFUSE-3 trialsHealth Stroke ScalePost-stroke mortalityIschemic stroke mortalityEffect of alteplaseRisk of mortalityLogistic regression modelsAnn NeurolFAST-MAGIMS IIISevere ISHospital mortalityIntravenous alteplaseSevere strokeStroke ScaleStroke severityFunctional outcome
2019
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure
Awad I, Polster S, Carrión-Penagos J, Thompson R, Cao Y, Stadnik A, Money P, Fam M, Koskimäki J, Girard R, Lane K, McBee N, Ziai W, Hao Y, Dodd R, Carlson A, Camarata P, Caron J, Harrigan M, Gregson B, Mendelow A, Zuccarello M, Hanley D, Abdul-Rahim A, Abou-Hamden A, Abraham M, Ahmed A, Alba C, Aldrich E, Ali H, Altschul D, Amin-Hanjani S, Anderson C, Anderson D, Ansari S, Antezana D, Ardelt A, Arikan F, Avadhani R, Baguena M, Baker A, Barrer S, Barzo P, Becker K, Bergman T, Betz J, Bistran-Hall A, Boström A, Braun J, Brindley P, Broaddus W, Brown R, Buki A, Bulters D, Cao B, Carhuapoma J, Chalela J, Chang T, Chicoine M, Chorro I, Chowdhry S, Cobb C, Corral L, Csiba L, Davies J, Dawson J, Díaz A, Dierdeyn C, Diringer M, Dlugash R, Ecker R, Economas T, Enriquez P, Ezer E, Fan Y, Feng H, Franz D, Freeman W, Fusco M, Galicich W, Gandhi D, Gelea M, Goldstein J, Gonzalez A, Grabarits C, Greenberg S, Gregson B, Gress D, Gu E, Gupta G, Hall C, Harnof S, Hernandez F, Hoesch R, Hoh B, Houser J, Hu R, Huang J, Huang Y, Hussain M, Insinga S, Jadhav A, Jaffe J, Jahromi B, Jallo J, James M, James R, Janis S, Jankowitz B, Jeon E, Jichici D, Jonczak K, Jonker B, Karlen N, Kase C, Keric N, Kerz T, Kitagawa R, Knopman J, Koenig C, Krishnamurthy S, Kumar A, Kureshi I, Laidlaw J, Lakhanpal A, Latorre J, LeDoux D, Lees K, Leifer D, Leiphart J, Lenington S, Li Y, Lopez G, Lovick D, Lumenta C, Luo J, Maas M, MacDonald J, MacKenzie L, Madan V, Majkowski R, Major O, Malhorta R, Malkoff M, Mangat H, Maswadeh A, Matouk C, Mayo S, McArthur K, McCaul S, Medow J, Mezey G, Mighty J, Miller D, Mitchell P, Mohan K, Mould W, Muir K, Muñoz L, Nakaji P, Nee A, Nekoovaght-Tak S, Nyquist P, O'Kane R, Okasha M, O'Kelly C, Ostapkovich N, Pandey A, Parry-Jones A, Patel H, Perla K, Pollack A, Pouratian N, Quinn T, Rajajee V, Reddy K, Rehman M, Reimer R, Rincon F, Rosenblum M, Rybinnik I, Sanchez B, Sansing L, Sarabia R, Schneck M, Schuerer L, Schul D, Schweitzer J, Seder D, Seyfried D, Sheth K, Spiotta A, Stechison M, Sugar E, Szabo K, Tamayo G, Tanczos K, Taussky P, Teitelbaum J, Terry J, Testai F, Thomas K, Thompson C, Thompson G, Torner J, Tran H, Tucker K, Ullman N, Ungar L, Unterberg A, Varelas P, Vargas N, Vatter H, Venkatasubramanian C, Vermillion K, Vespa P, Vollmer D, Wang W, Wang Y, Wang Y, Wen J, Whitworth L, Willis B, Wilson A, Wolfe S, Wrencher M, Wright S, Xu Y, Yanase L, Yenokyan G, Yi X, Yu Z, Zomorodi A. Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery 2019, 84: nyz077-. PMID: 30891610, PMCID: PMC6537634, DOI: 10.1093/neuros/nyz077.Peer-Reviewed Original ResearchConceptsRecombinant tissue plasminogen activatorTissue plasminogen activatorICH volumeImproved mortalityIntracerebral hemorrhageFunctional outcomePlasminogen activatorFunctional outcome benefitsInitial hematoma volumeHistory of hypertensionBenefits of surgeryType of strokeDisease severity factorsSurgical performanceVolume reductionAlteplase dosesMRS 0Mortality benefitPrimary outcomeHematoma evacuationCatheter aspirationHematoma volumeICH evacuationOutcome benefitsSurgical arm
2013
Pilot Study of Intravenous Glyburide in Patients With a Large Ischemic Stroke
Sheth KN, Kimberly WT, Elm JJ, Kent TA, Mandava P, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, Simard JM, Stern BJ. Pilot Study of Intravenous Glyburide in Patients With a Large Ischemic Stroke. Stroke 2013, 45: 281-283. PMID: 24193798, PMCID: PMC4235339, DOI: 10.1161/strokeaha.113.003352.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood GlucoseBrain EdemaBrain IschemiaComorbidityFemaleFibrinolytic AgentsGlyburideHumansHypoglycemiaHypoglycemic AgentsInjections, IntravenousMagnetic Resonance ImagingMaleMiddle AgedPatient SafetyPilot ProjectsProspective StudiesStrokeTissue Plasminogen ActivatorTreatment OutcomeWhite PeopleYoung AdultConceptsIschemic strokeLesion volumeIntravenous recombinant tissue-type plasminogen activatorRecombinant tissue-type plasminogen activatorIpsilateral hemisphere volumeLarge ischemic strokeSerious adverse eventsAcute ischemic strokeRetrospective clinical dataFeasibility of recruitingTissue-type plasminogen activatorIntravenous glyburideSevere strokeSymptomatic hypoglycemiaAdverse eventsFocal ischemiaMean ageClinical trialsHemisphere volumeClinical dataDose reductionAge 18PatientsSulfonylurea receptorPlasminogen activator